Abcam, ab267297, Human MYSM1 knockout HEK-293T cell line

Size: 2 x 1000000Cells / vial / 1000000Cells / vial
MYSM1 KO cell line available to order. KO validated by. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 8 and 2 bp insertion in exon 8. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 8 and 2 bp insertion in exon 8

Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-MYSM1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
MYSM1 also known as Myb-like SWIRM and MPN domains 1 functions as a histone H2A deubiquitinase. This protein weighs approximately 83 kDa. MYSM1 is found in the nucleus and shows expression in various tissues including hematopoietic cells such as T cells and bone marrow. By removing ubiquitin from histone H2A MYSM1 influences chromatin structure and gene transcription.
Biological function summary
MYSM1 plays an important role in regulating gene expression during processes like hematopoiesis and immune development. It forms part of a chromatin remodeling complex that modulates transcriptional activity by altering nucleosome configuration. This function is essential for proper stem cell maintenance and differentiation by ensuring that transcriptionally active and inactive regions are appropriately maintained and accessed.
Pathways
MYSM1 participates in the ubiquitin-proteasome pathway and is involved in DNA damage response. It associates closely with proteins like TP53 where it aids in governing cell cycle progression and apoptosis. MYSM1 also interacts with histone modification machinery exerting effects on transcriptional silencing and activation particularly influencing genes associated with immune cell lineage commitment.
MYSM1 impacts conditions such as bone marrow failure and immunodeficiency. It connects with the TP53 protein where mutations or dysregulation in this pathway can lead to hematological abnormalities and impaired immune function. MYSM1 deficiency has been implicated in defective T cell maturation and aberrant myeloid lineage decisions contributing to these disorders.